Toxic epidermal necrolysis during chemo-immunotherapy treatment with pembrolizumab
Journal of Oncology Pharmacy Practice
Published online on February 20, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionImmune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, improve survival in patients with advanced malignancies. However, their combination with chemotherapy may increase the incidence of severe immune-related adverse events (...
IntroductionImmune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, improve survival in patients with advanced malignancies. However, their combination with chemotherapy may increase the incidence of severe immune-related adverse events (...